Ubiquitination and deubiquitination in cancer: from mechanisms to novel therapeutic approaches
Open accessThe DOI matches its Crossref record; 467 of the 467 references it cites were found in a registry or an index.
Abstract
Ubiquitination, a pivotal posttranslational modification of proteins, plays a fundamental role in regulating protein stability. The dysregulation of ubiquitinating and deubiquitinating enzymes is a common feature in various cancers, underscoring the imperative to investigate ubiquitin ligases and deubiquitinases (DUBs) for insights into oncogenic processes and the development of therapeutic interventions. In this review, we discuss the contributions of the ubiquitin–proteasome system (UPS) in all hallmarks of cancer and progress in drug discovery. We delve into the multiple functions of the UPS in oncology, including its regulation of multiple cancer-associated pathways, its role in metabolic reprogramming, its engagement with tumor immune responses, its function in phenotypic plasticity and polymorphic microbiomes, and other essential cellular functions. Furthermore, we provide a comprehensive overview of novel anticancer strategies that leverage the UPS, including the development and application of proteolysis targeting chimeras (PROTACs) and molecular glues.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 401–467 of 467
Sha, B., Chen, X., Wu, H., Li, M., Shi, J., Wang, L., Liu, X., Chen, P., Hu, T., & Li, P. (2019) · APOPTOSIS · doi:10.1007/s10495-019-01561-9 · Cited by 32
Self-citationZhang, W., Li, L., Cai, L., Liang, Y., Xu, J., Liu, Y., Zhou, L., Ding, C., Zhang, Y., Zhao, H., et al. (2021) · Cell Death and Differentiation · doi:10.1038/s41418-020-00724-5 · Cited by 32
SETDB1 Modulates Degradation of Phosphorylated RB and Anticancer Efficacy of CDK4/6 Inhibitors
Huang, Z., Li, X., Tang, B., Li, H., Zhang, J., Sun, R., Ma, J., Pan, Y., Yan, B., Zhou, Y., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-0264 · Cited by 32
Self-citationWang, Y., Jia, Z., Liang, C., He, Y., Cong, M., Wu, Q., Tian, P., He, D., Miao, X., Sun, B., et al. (2023) · Cell Discovery · doi:10.1038/s41421-022-00507-x · Cited by 32
Li, T., Jin, K., Zhou, H.-Y., Liao, Z., Zhang, H., Shi, S., Lin, M.-X., Chai, S., Fei, Q., Ye, L., et al. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216411 · Cited by 32
Zhou, T., Chen, T., Lai, B., Zhang, W., Luo, X., Ding, X., Fu, W., & Xu, J. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04320-3 · Cited by 31
Xue, Y., Li, M., Hu, J., Song, Y., Guo, W., Miao, C., Ge, D., Hou, Y., Wang, X., Huang, X., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05174-0 · Cited by 31
Targeting Cul3-scaffold E3 ligase complex via KLHL substrate adaptors for cancer therapy
Xiang, S., Shi, X., Chen, P., Chen, Y., Bing, S., Jin, X., Cao, J., Wang, J., Yang, B., Shao, X., et al. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105616 · Cited by 30
Overview of PROTACs Targeting the Estrogen Receptor: Achievements for Biological and Drug Discovery
Qin, H., Zhang, Y., Lou, Y., Pan, Z., Song, F., Liu, Y., Xu, T., Zheng, X., Hu, X., & Huang, P. C. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867328666211110101018 · Cited by 30
OTUD6A promotes prostate tumorigenesis via deubiquitinating Brg1 and AR
Fu, X., Zhao, J., Yu, G., Zhang, X., Sun, J., Li, L., Yin, J., Niu, Y., Ren, S., Zhu, Y., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03133-1 · Cited by 30
Self-citationSun, T., Zhang, K., Li, W., Liu, Y., Pangeni, R. P., Li, A., Arvanitis, L. D., & Raz, D. J. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-022-00946-9 · Cited by 30
Jiang, Z., Peng, T., Qian, H., Lu, C., Qiu, F. X., & Zhang, S. (2019) · Cancer Cell International · doi:10.1186/s12935-019-0878-y · Cited by 29
MARCH6 promotes Papillary Thyroid Cancer development by destabilizing DHX9
Liu, Y., Xu, S., Huang, Y. S., Liu, S., Xu, Z.-G., Wei, M., & Liu, J. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.60628 · Cited by 29
The Shelterin Component TPP1 Is a Binding Partner and Substrate for the Deubiquitinating Enzyme USP7
Zemp, I., & Lingner, J. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.596056 · Cited by 28
Zhao, H., Zheng, C., Wang, Y., Hou, K., Yang, X., Cheng, Y., Che, X., Xie, S., Wang, S., Zhang, T., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00181 · Cited by 28
Self-citationPost-Translational Regulation of ARF: Perspective in Cancer
Seo, J., Seong, D., Lee, S. R., Oh, D., & Song, J. (2020) · Biomolecules · doi:10.3390/biom10081143 · Cited by 28
Cheng, X. C., Zhang, B., Guo, F., Wu, H., & Jin, X. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13149 · Cited by 28
He, Y., Jin, Y., Zhang, Y., Meng, H., Zhao, B., Jiang, Y., Zhu, J.-W., Liang, G.-Y., Kong, D., & Jin, X. (2014) · Translational research · doi:10.1016/j.trsl.2014.09.005 · Cited by 27
Jones, R. J., Gu, D., Bjorklund, C. C., Kuiatse, I., Remaley, A. T., Bashir, T., Vreys, V., & Orlowski, R. Z. (2013) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.204958 · Cited by 26 · cited 1×
“Clinical research on human cell lymphoma and multiple leiomyomas is underway [454, 459].”
BackgroundANKRD9 is associated with tumor suppression as a substrate receptor subunit of ubiquitin ligase
Lee, Y., Lim, B., Lee, S., Lee, W. R., Kim, Y., Kim, M., Ju, H., Kim, M. Y., Kang, S., Song, J., et al. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.07.001 · Cited by 26
USP7 stabilizes EZH2 and enhances cancer malignant progression.
Zheng, N., Chu, M., Lin, M., He, Y., & Wang, Z. P. (2020) · PubMed Central · Cited by 26
A20 and RBX1 Regulate Brentuximab Vedotin Sensitivity in Hodgkin Lymphoma Models
Wei, W., Lin, Y., Song, Z., Xiao, W., Chen, L., Yin, J., Zhou, Y., Barta, S. K., Petrus, M. N., Waldmann, T. A., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-4137 · Cited by 26
Bendell, J. C., Ervin, T. J., Senzer, N. N., Richards, D., Firdaus, I., Lockhart, A. C., Cohn, A. L., Saleh, M. N., Gardner, L. R., Sportelli, P., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.18_suppl.lba3501 · Cited by 26
Liu, J., Zhou, T., Dong, X. D., Guo, Q., Zheng, L., Wang, X., Zhang, N., Li, D., Ren, L., Yi, F., et al. (2023) · Oncogene · doi:10.1038/s41388-023-02667-w · Cited by 26
Self-citationLv, T., Zhang, B., Jiang, C., Zeng, Q., Yang, J., & Zhou, Y. (2023) · International Journal of Oncology · doi:10.3892/ijo.2023.5561 · Cited by 26
Wang, Z., Wang, M., Geng, Y., Ye, C.-Y., & Zang, Y. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03608-z · Cited by 25
E2 enzymes in genome stability: pulling the strings behind the scenes
Osborne, H. C., Irving, E., Forment, J. V., & Schmidt, C. K. (2021) · Trends in Cell Biology · doi:10.1016/j.tcb.2021.01.009 · Cited by 24
Wu, H., Jiao, Y., Guo, X., Wu, Z., & Lv, Q. (2024) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.18112 · Cited by 23
Zheng, Z. G., Shang, Y., Xu, R., Yan, X., Wang, X., Cai, J., Bai, Z., Liu, X., Yin, J., Zhang, J., et al. (2022) · PubMed · Cited by 22
Biology of Pellino1: a potential therapeutic target for inflammation in diseases and cancers
Yan, L., Cui, Y., & Feng, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1292022 · Cited by 22
Gopalan, B., Shanker, M., Scott, A. W., Branch, C. D., Chada, S., & Ramesh, R. (2007) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7701095 · Cited by 21
Hatta, M. N. A., Hanif, E. A. M., Chin, S., Low, T. Y., & Neoh, H. (2023) · Bioscience Reports · doi:10.1042/bsr20230609 · Cited by 20
Lu, Y., Su, F., Cheng, Z., Yang, J., Dai, H., Yang, J., Zhang, T., & Bai, Y. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122111 · Cited by 20
Pei, L., Zhao, F., & Zhang, Y. (2023) · APOPTOSIS · doi:10.1007/s10495-023-01873-x · Cited by 20
Song, Z., Wei, W., Xiao, W., Al-Saleem, E. D., Nejati, R., Chen, L., Yin, J., Fabrizio, J., Petrus, M. N., Waldmann, T. A., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2014470117 · Cited by 19
Pápai, Z., Chen, L.-C., Costa, D. D., Blotner, S. D., Vazvaei, F., Gleave, M., Jones, R., & Zhi, J. (2019) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-019-03851-0 · Cited by 18
Phase 1 study of the MDM2 antagonist RO6839921 in patients with acute myeloid leukemia
Uy, G. L., Assouline, S., Young, A.-M., Blotner, S., Higgins, B., Chen, L.-C., & Yee, K. (2020) · Investigational New Drugs · doi:10.1007/s10637-020-00907-4 · Cited by 18
USP25 Regulates EGFR Fate by Modulating EGF-Induced Ubiquitylation Dynamics
Niño, C. A., Wollscheid, N., Giangreco, G., Maspero, E., & Polo, S. (2020) · Biomolecules · doi:10.3390/biom10111548 · Cited by 18
Blotner, S. D., Chen, L.-C., Ferlini, C., & Zhi, J. (2018) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-018-3534-7 · Cited by 16
Moschos, S. J., Sandhu, S. K., Lewis, K. D., Sullivan, R. J., Puzanov, I. J., Johnson, D. B., Henary, H. A., Wong, H. L., Upreti, V. V., Long, G. V., et al. (2022) · Investigational New Drugs · doi:10.1007/s10637-022-01253-3 · Cited by 16
Faessel, H. M., Nemunaitis, J. J., Bauer, T. M., Lockhart, A. C., Faller, D. V., Sedarati, F., Zhou, X., Venkatakrishnan, K., & Harvey, R. D. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13915 · Cited by 15
Honokiol Inhibits Melanoma Growth by Targeting Keratin 18 in vitro and in vivo
Liu, T., Liu, H., Wang, P., Hu, Y., Yang, R., Liu, F., Kim, H. G., Dong, Z., & Liu, K. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.603472 · Cited by 15
Self-citationCHIP and BAP1 Act in Concert to Regulate INO80 Ubiquitination and Stability for DNA Replication
Seo, H.-R., Jeong, D., Lee, S., Lee, H.-S., Lee, S.-A., Kang, S. W., & Kwon, J. (2021) · Molecules and Cells · doi:10.14348/molcells.2021.2258 · Cited by 15
Tognon, C. E., Rafn, B., Cetinbas, N. M., Kamura, T., Trigo, G., Rotblat, B., Okumura, F., Matsumoto, M., Chow, C., Davare, M. A., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra117.000321 · Cited by 14
Sarri, N., Wang, K., Tsioumpekou, M., Castillejo-López, C., Lennartsson, J., Heldin, C., & Papadopoulos, N. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04128-1 · Cited by 14
Zeng, X. R., Zheng, W. L., Sheng, Y., & Ma, H. (2022) · Bioengineered · doi:10.1080/21655979.2022.2048991 · Cited by 14
Ubiquitination is a major modulator for the activation of inflammasomes and pyroptosis
Jiang, Q., Zhu, Z., & Mao, X. (2023) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2023.194955 · Cited by 14
Wang, C., Xiao, H., Ma, J., Zhu, Y., Yu, J., Sun, L., Sun, H., Liu, Y., Jin, C., & Huang, H. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.03.096 · Cited by 13
Self-citationKon, S., Kobayashi, N., & Satake, M. (2014) · Cellular Logistics · doi:10.4161/cl.28461 · Cited by 12
USP14 Regulates Cancer Cell Growth in a Fatty Acid Synthase-Independent Manner
Yang, J. S., Yoon, N., Kong, M., Jung, B. H., Lee, H., & Park, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413437 · Cited by 12
Morita, S., Minami, H., Mitsuma, A., Toyoda, M., Kiyota, N., & Ando, Y. (2022) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.13744 · Cited by 12
Sekiguchi, N., Kasahara, S., Miyamoto, T., Kiguchi, T., Ohno, H., Takagi, T., Tachibana, M., Sumi, H., Kakurai, Y., Yamashita, T., et al. (2022) · International Journal of Hematology · doi:10.1007/s12185-022-03464-z · Cited by 12
Fischer, S., Trinh, V. T., Simon, C., Weber, L. M., Forné, I., Nist, A., Bange, G., Abendroth, F., Stiewe, T., Steinchen, W., et al. (2023) · Cell chemical biology · doi:10.1016/j.chembiol.2023.05.012 · Cited by 12
Turowec, J. P., Lau, E. W. T., Wang, X., Brown, K. R., Fellouse, F. A., Jawanda, K. K., Pan, J., Moffat, J., & Sidhu, S. S. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.004420 · Cited by 10
Emerging Roles of Non-proteolytic Ubiquitination in Tumorigenesis
Yin, X., Liu, Q., Liu, F., Tian, X., Yan, T., Han, J., & Jiang, S. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.944460 · Cited by 10
Self-citationLiu, X., Lu, R., Yang, Q., He, J., Huang, C., Cao, Y., Zhou, Z., Huang, J., Li, L., Chen, R., et al. (2023) · Molecular Oncology · doi:10.1002/1878-0261.13543 · Cited by 10
Model‐based assessments of CYP3A‐mediated drug‐drug interaction risk of milademetan
Hong, Y., Ishizuka, T., Watanabe, A., Tachibana, M., Lee, M., Ishizuka, H., LaCreta, F. P., & Abutarif, M. A. (2021) · Clinical and Translational Science · doi:10.1111/cts.13082 · Cited by 9
Mcl‐1 inhibition overcomes BET inhibitor resistance induced by low FBW7 expression in breast cancer
Wang, X., Wei, X., Cao, Y. Q., & Xing, P. (2022) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17210 · Cited by 8
RBCK1 regulates the progression of ER-positive breast cancer through the HIF1α signaling
Niu, Z., Fan, J., Chen, F., Yang, H., Li, X., Zhuang, T., Guo, C., Cao, Q., Zhu, J., Wang, H., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05473-6 · Cited by 8
Li, S., Shi, L., Wang, Y., Zhang, L., Chu, S., Li, M., Bai, J., & Zhu, W. (2023) · Experimental Cell Research · doi:10.1016/j.yexcr.2023.113719 · Cited by 8
Telomere shortening and expression of TRF1 and TRF2 in uterine leiomyoma
Oh, B.-K., Choi, Y., & Choi, J. S. (2021) · Molecular Medicine Reports · doi:10.3892/mmr.2021.12243 · Cited by 7
Yang, H., Liu, Y., Yang, J., Zhang, Q. H., Wang, H., Chen, Y., & Zhou, K. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.05.111 · Cited by 7
Elongin B promotes breast cancer progression by ubiquitinating tumor suppressor p14/ARF
Sui, X.-Y., Ma, X.-Y., Hou, Y., Cao, S.-W., Wang, Z.-Q., Jia, L., Fan, L., Shao, Z.-M., & Zhang, W. (2024) · Cell Biology and Toxicology · doi:10.1007/s10565-024-09864-7 · Cited by 7
OTUD3 suppresses the mTORC1 signaling by deubiquitinating KPTN
Li, J., Yang, D., Lin, Y., Xu, W., Zhao, S., & Wang, C. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1337732 · Cited by 5
Erratum To: USP26 regulates TGF‐β signaling by deubiquitinating and stabilizing SMAD7
Lui, S. K. L., Iyengar, P. V., Jaynes, P. W., Isa, Z. F. B. A., Pang, B., Tan, T. Z., & Eichhorn, P. J. A. (2019) · EMBO Reports · doi:10.15252/embr.201949618 · Cited by 4
Gundle, K. R., Rajasekaran, K., Houlton, J. J., Deutsch, G. B., Ow, T. J., Maki, R. G., Pang, J., Nathan, C. O., Clayburgh, D. R., Newman, J. G., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1367581 · Cited by 4
Zhou, X., Richardson, D. L., Dowlati, A., Goel, S., Sahebjam, S., Strauss, J. F., Chawla, S. P., Wang, D., Mould, D. R., Samnotra, V., et al. (2022) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.1194 · Cited by 3
Metadata
- Authors
- Liu, F., Chen, J., Li, K., Li, H., Zhu, Y., Zhai, Y., Lu, B., Fan, Y., Liu, Z., Chen, X., Jia, X., Dong, Z., & Liu, K.
- Venue
- Molecular Cancer
- Published
- 2024-07-25
- Volume
- 23
- Issue
- 1
- Pages
- 148-148
- ISSN
- 1476-4598 (ISSN-L)
- OpenAlex
- W4400978852
- Cited by
- 326
- References
- 467
- FWCI
- 37.88
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.